In May 2016 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) published the European drug report 2016: trends and developments summarising  the latest trends across the 28 EU member states, and Norway and Turkey.¹  The report highlights the increasing use of MDMA following a period of decline in recent years, with greater levels of production helped by new sources of precursors and production techniques.  The drug’s popularity with existing stimulant users has grown and a new generation of users is emerging, presenting greater health risks as more high potency products become available.